Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 26

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 26
---
, the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and our research and development programs; |

| • |     | the anticipated timing of releasing data for current or future preclinical studies and clinical trials; |

| • |     | our ability to develop and advance product candidates through preclinical studies and into, and successfully 
 complete, clinical studies;                                                                                  |

| • |     | the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of FYARRO, 
 the ADC Programs and any other product candidates that we may develop in the future;                           |

| • |     | our ability to establish or maintain collaborations or strategic relationships or obtain additional funding; |

| • |     | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and |

| • |     | global economic volatility, macroeconomic political, legislative, and regulatory developments, geopolitical                                                    
 conflict or competitive pressures, or changes in such conditions, negatively affecting our markets, customers, business, operations and financial performance; |

- 16 -

| • |     | the period over which we anticipate our existing cash and cash equivalents will be sufficient to fund our 
 operating expenses and capital expenditure requirements;                                                  |

| • |     | our financial performance; |

| • |     | our belief that we presently have sufficient supply of FYARRO for at least the next two years based on our 
 estimated demand for PEComa sales; and                                                                     |

| • |     | other factors including but not limited to those detailed under the sections entitled “Risk 
 Factors” and “Aadi Risk Factors”.                                                           |

Further information regarding the risks, uncertainties and other factors that could cause actual results to differ from the results in these forward-looking statements are discussed under the section entitled “Risk Factors” set forth below, and for the reasons described elsewhere in this proxy statement. Please carefully consider these factors, as well as other information contained herein and in our periodic reports and documents filed with the SEC. All forward-looking statements and reasons why results may differ from expected results included in this proxy statement are made as of the date hereof. All of the forward-looking statements made in this proxy statement are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Aadi or its business or operations. Readers are cautioned not to